Hypoglycemia was uncommon and primarily observed in people concomitantly getting insulin secretagogues or insulin, according to the glucose-dependent system of action. Severe hypoglycemia was uncommon, supporting a good risk-benefit profile for both of those diabetic and non-diabetic populations.Ongoing refinement of formulation and dosing procedur